liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression of c-Kit discriminates between two functionally distinct subsets of human type 2 innate lymphoid cells
AstraZeneca, Sweden.
AstraZeneca, Sweden.
AstraZeneca, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Karolinska Inst, Sweden.
2019 (English)In: European Journal of Immunology, ISSN 0014-2980, E-ISSN 1521-4141, Vol. 49, no 6, p. 884-893Article in journal (Refereed) Published
Abstract [en]

Human type 2 innate lymphoid cells (ILC2) are the only ILC subset that shows heterogeneous expression of the SCF receptor c-Kit (CD117). Despite its use as surface marker to distinguish ILC populations, its influence on ILC2 biology has not been investigated. Here, we show that c-Kit expression of peripheral blood ILC distinguishes two functionally distinct ILC2 subsets (c-Kit(hi) and c-Kit(lo)). When examined for their potential for functional plasticity we found that c-Kit(lo) ILC2 displayed greater potential to produce type 2 cytokines, possibly representing fully mature and lineage committed ILC2. On the other hand, c-Kit(hi) ILC2 coexpressed the ILC3-marker and chemokine receptor CCR6 and were able to mount a significant IL-17A response under ILC3-promoting conditions. In addition, c-Kit(hi) ILC2 produced higher levels of IFN-gamma than c-Kit(lo) ILC2 under ILC1-conditions. Although costimulation with SCF did not further influence ILC2 plasticity, it augmented type 2 cytokine production. We conclude that c-Kit marks distinct subpopulations of ILC2, which has therapeutic implications for conditions in which ILC2 are involved, such as allergy and asthma.

Place, publisher, year, edition, pages
WILEY , 2019. Vol. 49, no 6, p. 884-893
Keywords [en]
c-Kit; CD117; IL-17A; innate lymphoid cells; plasticity
National Category
Immunology
Identifiers
URN: urn:nbn:se:liu:diva-158554DOI: 10.1002/eji.201848006ISI: 000470912000007PubMedID: 30892687OAI: oai:DiVA.org:liu-158554DiVA, id: diva2:1334897
Note

Funding Agencies|AstraZeneca (Gothenburg, Sweden)

Available from: 2019-07-03 Created: 2019-07-03 Last updated: 2019-07-03

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Mjösberg, Jenny
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health Sciences
In the same journal
European Journal of Immunology
Immunology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf